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ABSTRACT   
 
Background and purpose: Histone deacetylases (HDACs) silence genes by 
deacetylating lysine residues in histones and other proteins. HDAC inhibitors 
(HDACi) represent a new class of compounds with anti-inflammatory activity. This 
study investigated whether treatment with a broad spectrum HDACi, suberoylanilide 
hydroxamic acid (SAHA), prevents the cardiac fibrosis as part of the cardiovascular 
remodelling in deoxycorticosterone acetate (DOCA)-salt rats.   
Experimental approach: Control and DOCA-salt rats were treated with SAHA (25 mg 
kg
-1 
day
-1
 s.c.) for 32 days; changes in cardiovascular structure and function were 
determined. 
Key results: Administration of SAHA to DOCA-salt rats attenuated the following 
parameters: the increased concentration of over 20 pro-inflammatory cytokines in 
plasma, increased inflammatory cell infiltration and interstitial collagen deposition, 
increased passive diastolic stiffness, prolongation of action potential duration at 20% 
and 90% of repolarization, development of left ventricular hypertrophy, systolic 
hypertension and the changes in vascular dysfunction. 
Conclusions and implications: The HDAC inhibitor, SAHA, attenuated the 
cardiovascular remodelling associated with DOCA-salt hypertensive rats and 
improved cardiovascular structure and function, especially fibrosis, in the heart and 
blood vessels, possibly by suppressing inflammation. Control of cardiac histone or 
non-histone protein acetylation is a potential therapeutic approach to preventing 
cardiac remodelling, especially cardiac fibrosis. 
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Abbreviations 
CINC - cytokine-induced neutrophil chemoattractant 
HDACi – histone deacetylase inhibitor(s) 
IP - interferon-inducible protein 
MIP – macrophage inflammatory protein 
TIMP – tissue inhibitor of metalloproteinases 
LIX – LPS-induced CXC chemokine 
VEGF – vascular endothelial growth factor 
MIG – monokine induced by IFN-gamma 
sICAM – soluble intercellular adhesion molecule 
 
INTRODUCTION 
 
Chronic pathophysiological stress often leads to excessive collagen deposition 
(fibrosis) in the left ventricle of the heart,
 
as part of the process of cardiovascular 
remodelling. Cardiac fibrosis is thought to be initiated by the actions of pro-
inflammatory cytokines leading to fibroblast activation and infiltrating inflammatory 
cells (Brown et al, 2005a; Hinglais et al, 1994; Kanzaki et al, 2001; Ratcliffe et al, 
2000). The common sequence of events that occurs in response to an inflammatory 
insult can be summarized as haemostasis; recruitment of circulating immune-
inflammatory cells; macrophage activation; activation of fibroblasts and formation of 
a provisional matrix; and remodelling of the granulomatous scar (Brown et al, 2005b). 
This remodelling of the heart and blood vessels ultimately leads to a decrease in 
ventricular compliance together with ventricular hypertrophy, conduction 
abnormalities, increased blood pressure and endothelial dysfunction (Weber, 1996; 
Weber et al, 1993).  
 
Inflammatory gene expression, DNA repair and proliferation may be controlled by the 
degree of acetylation of histone and non-histone proteins produced by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) (Adcock, 2007; Halili 
et al, 2009). HDAC inhibitors (HDACi) represent a new class of anti-cancer drugs 
with pleiotropic anti-inflammatory responses. HDACi prevent pro-inflammatory 
cytokine production with therapeutic effects reported in animal models of 
inflammatory diseases (Adcock, 2007; Blanchard & Chipoy, 2005; Lin et al, 2007; 
Halili et al, 2009; Tong et al, 2004). Pro-inflammatory cytokines assist in the 
infiltration of inflammatory cells into the myocardium (Nicoletti & Michel, 1999; 
Rutschow et al, 2006; Westermann et al, 2006). This initiates an inflammatory 
cascade liberating arachidonic acid and metabolites such as 12-lipoxygenase and 5-
lipoxygenase derivatives, cysteinyl leukotrienes and thromboxanes with well-defined 
profibrotic properties (Cruz-Gervis et al, 2002; Levick et al, 2006; Wen et al, 2003). 
The precise HDAC isoforms responsible for cardiovascular remodelling in vivo are 
not known, with evidence that class I (HDACs 1, 2, 3, 8 and 11), II (HDACs 4, 5, 6, 
7, 9, 10) and III (sirtuins) generally have pro-hypertrophic, anti-hypertrophic and anti-
apoptotic functions in cardiomyocytes, respectively (McKinsey & Kass, 2007; Verdin 
et al, 2003; Zhang et al, 2002). Some HDACi have been shown to blunt cardiac 
hypertrophy (Antos et al, 2003; Gallo et al, 2008; Kee et al, 2006; Kong et al, 2006), 
but those studies did not consider the possibility that the anti-inflammatory effects of 
HDACi could control fibrosis and improve cardiac function. The development of 
HDACi with selectivity for individual isoforms is still in its infancy. It is also worth 
noting that there are relatively few truly HDAC-selective compounds and many of 
those that have been reported to show some selectivity in vitro against different 
HDAC enzymes have been found by us (Fairlie, Sweet et al; unpublished work) to be 
fairly toxic to normal human cells (cardiomyocytes, macrophages).  
 
The present study has investigated whether the FDA-approved HDAC inhibitor, 
suberoylanilide hydroxamic acid (SAHA), prevents cardiovascular remodelling and 
improves cardiac function in DOCA-salt rats. SAHA is a broad-spectrum (class I and 
II) inhibitor of HDAC with moderate potency (IC50 ~100 nM) that is being used to 
treat T-cell lymphoma (Richon, 2006). Unlike most HDAC inhibitors, SAHA is also 
relatively non-toxic to normal cells and was therefore an appropriate choice for our in 
vivo study reported here. The present study establishes that SAHA decreases DOCA-
induced cardiovascular remodelling in rats, as demonstrated by reductions in the 
increased systolic blood pressure, collagen deposition, cardiac stiffness, left 
ventricular hypertrophy, action potential duration and vascular dysfunction that are 
characteristic of the DOCA-salt rat as well as decreasing expression of inflammatory 
cytokines. These findings suggest that inhibition of class I and II HDACs may present 
a novel approach to preventing the development of these key indicators of 
cardiovascular remodelling.  
 
MATERIALS AND METHODS 
 
DOCA-salt hypertensive rats 
 
Male Wistar rats (8–10 wk old) were obtained from the Central Animal Breeding 
House of The University of Queensland. All experimental protocols were approved by 
the Animal Experimentation Ethics Committee of The University of Queensland 
under the guidelines of the National Medical and Health Research Council, Australia. 
Rats were given ad libitum access to food and water and were housed in 12-h 
light/dark conditions. All treated rats were uninephrectomized. The rats were 
anesthetized with an intraperitoneal injection of Zoletil (tiletamine (25 mg kg
-1
) and 
zolazepam (25 mg kg
-1
)) together with xylazine (10 mg kg
-1
, Rompun); a lateral 
abdominal incision provided access to the kidney, and the left renal vessels and ureter 
were ligated. The left kidney was removed and weighed, and the incision site was 
sutured. Uninephrectomized rats were given no further treatment or were given 1% 
NaCl in the drinking water with subcutaneous injections of deoxycorticosterone 
acetate (DOCA) (25 mg in 0.4 ml of dimethylformamide every 4th day, DOCA-salt 
rats). SAHA (25 mg kg
-1
 dissolved in 80% dimethylformamide) was administered 
daily as a subcutaneous injection for 32 days, starting 4 days before surgery until 
experiments. Experiments were performed 28 days after surgery, as in previous 
studies (Chan et al, 2006; Fenning et al, 2005; Loch et al, 2007). 
 
Assessment of physiological parameters 
 
Body weight, food and water intakes were measured daily. Systolic blood pressure 
was measured after 0, 2 and 4 weeks under light sedation with i.p. injection of Zoletil 
(tiletamine 15 mg kg
-1
, zolazepam 15 mg kg
-1
), using an MLT1010 Piezo-Electric 
Pulse Transducer (ADInstruments) and inflatable tail-cuff connected to a MLT844 
Physiological Pressure Transducer (ADInstruments) and PowerLab data acquisition 
unit (ADInstruments, Sydney, Australia). Rats were killed with an injection of 
pentobarbitone sodium (100 mg kg
-1
 ip). Blood was taken from the abdominal aorta 
and centrifuged, and the plasma was frozen. Plasma malondialdehyde concentrations 
were determined by HPLC (Sim et al, 2003). 
 
Isolated heart preparation 
 
The left ventricular function of the rats in all treatment groups was assessed using the 
Langendorff heart preparation. Terminal anaesthesia was induced via i.p. injection of 
pentobarbitone sodium 100 mg kg
-1
 (Lethabarb ®). Once anaesthesia was achieved, 
heparin (1000 IU) was injected into the right femoral vein. Isovolumetric ventricular 
function was measured by inserting a latex balloon catheter into the left ventricle 
connected to a Capto SP844 MLT844 physiological pressure transducer and Chart 
software on a Maclab system. All left ventricular end-diastolic pressure values were 
measured by pacing the heart at 250 beats per minute using an electrical stimulator. 
End-diastolic pressures were obtained starting from 0mmHg up to 30mmHg. The 
right and left ventricles were separated and weighed. Diastolic stiffness constant (, 
dimensionless) was calculated as in previous studies (Chan et al, 2006; Fenning et al, 
2005; Loch et al, 2007).  
 
Microelectrode studies on isolated left ventricular papillary muscles 
 
Terminal anaesthesia was induced via i.p. injection of pentobarbitone sodium 100 mg 
kg
-1
 (Lethabarb®). The thorax was opened quickly, and the heart was removed. The 
left ventricular papillary muscles were quickly dissected in cold Tyrode physiological 
salt solution (in mM: 136.9 NaCl, 5.4 KCl, 1.0 MgCl2·H2O, 0.4 NaH2PO4·2H2O, 22.6 
NaHCO3, 1.8 CaCl2·2H2O, 5.5 glucose, 0.3 ascorbic acid, and 0.05 Na2EDTA) 
bubbled with 95% O2-5% CO2. Action potential duration (APD) at 20%, 50%, and 
90% of repolarization, action potential amplitude, and action potential voltage over 
time (dV/dtmax) was calculated as in previous studies (Fenning et al, 2005; Woolf et 
al, 2006). Contractile parameters measured were force of contraction and rate of 
change of force of contraction (dF/dt). 
 
Organ bath studies 
 
Thoracic aortic rings (4 mm in length) were suspended in an organ bath chamber with 
a resting tension of 10 mN. Cumulative concentration-response (contraction) curves 
were measured for noradrenaline; response (relaxation) curves were measured for 
acetylcholine and sodium nitroprusside in the presence of a submaximal (70%) 
contraction to noradrenaline (Allan et al, 2005; Chan et al, 2006). 
 
Organ weights 
 
Following euthanasia, the heart, liver, kidneys and spleen were removed and blotted 
dry for weighing. Organ weights were normalized relative to the body weight at the 
time of their removal (in mg g
-1
). 
 
Histology 
 
Tissues were initially fixed for 3 days in Telly’s fixative (100 ml of 70% ethanol, 5ml 
of glacial acetic acid and 10 ml of 40% formaldehyde) and then transferred into 
modified Bouin’s fluid (85 ml of saturated picric acid, 5ml glacial acetic acid and 10 
ml of 40% formaldehyde) for 2 days. The samples were then dehydrated and 
embedded in paraffin wax. Thin sections (10 m) of left ventricle were cut and 
stained with haematoxylin and eosin for determination of inflammatory cell 
infiltration. Monocytes and macrophages were identified by a trained observer under a 
high power (100X objective) microscope. Thick sections (15 m) were cut, stained 
with picrosirius red and image analysis under the laser scanning microscope was 
performed as previously described (Levick et al, 2006; Loch et al, 2006).  
 
Cytokine analysis 
 
Cytokines were detected in rat sera using Proteome Profiler Rat Cytokine Array 
Panel A (R&D Systems, MN, USA) according to manufacturer’s instructions. Briefly, 
nitrocellulose membranes were incubated with 800 L of rat sera overnight at 4C 
with 15 L of detection antibody cocktail. After washing, streptavidin-HRP and 
chemiluminescent detection reagent were added sequentially. Multiple exposures to 
X-ray film were made for up to 30 min. Densitometric analysis of array images was 
performed using Java-based ImageJ version1.40g from NIH. The relative change in 
cytokine concentrations between sera from DOCA-salt rats ± SAHA treatment were 
measured and are presented as mean  SEM of three independent experiments (n = 3). 
The rat proteins that could be monitored by this kit were limited to 29 inflammatory 
markers: interleukins (1, 1, 1ra, 2, 3, 4, 6, 10, 13, 17), TNF, IFN, GMCSF, 
RANTES, cytokine-induced neutrophil chemoattractants (CINC 1-3), interferon-
inducible protein (IP10), macrophage inflammatory proteins (MIP1, 3), tissue 
inhibitor of metalloproteinases (TIMP1), LPS-induced CXC chemokine (LIX), 
vascular endothelial growth factor (VEGF), monokine induced by IFN-gamma 
(MIG), soluble intercellular adhesion molecule (sICAM), L-selectin, CNTF, thymus 
chemokine and fractalkine. In further experiments, the RayBio Human Cytokine 
Antibody Array was used to detect whether treatment with SAHA at 5 or 50 M for 
10h changed the expression of both pro- and active forms of human matrix 
metalloproteinases (MMP)-1, -2, -3, -8, -10 and -13 or tissue inhibitor of matrix 
metalloproteinases (TIMP)-1, -2 and -4 in culture medium of human monocyte-
derived macrophages. In addition, gelatin zymography experiments were performed 
to assess the effect of SAHA at 5-500 M on purified active human recombinant 
MMP-2 and 9 activity.  
 Statistical analysis 
 
All data sets were represented as mean ± standard error of mean (SEM). Comparisons 
of findings between groups were made via statistical analysis of data sets using one-
way/two-way analysis of variance followed by the Duncan test to determine 
differences between treatment groups. A p-value of <0.05 was considered as 
statistically significant. 
 
Drugs 
Synthesis of SAHA 
A mixture of aniline and suberic acid was melted at 190°C for 10 min and then, after 
cooling, the suberanilic acid was separated from suberic dianilide by extraction into 
aqueous KOH before acidification. The suberanilic acid was esterified (EtOH/H2SO4) 
and subsequently treated with hydroxylamine to produce the hydroxamic acid 
(SAHA). The product showed no impurities either by reversed phase HPLC, NMR 
(1H, 13C) spectroscopy or mass spectrometry. Spectral data was in agreement with 
literature values (Stowell et al, 1995). 
 
DOCA, heparin, noradrenaline, acetylcholine and sodium nitroprusside were 
purchased from Sigma Chemical Company (St Louis, MO, U.S.A.). Noradrenaline, 
acetylcholine and sodium nitroprusside were dissolved in distilled water. DOCA was
 
dissolved in dimethylformamide with mild heating.  
 
RESULTS 
 
Biometrics 
 
DOCA-salt treated rats showed an increased water intake and failed to gain weight, as 
in previous studies (Table 1; Fenning et al., 2005; Mirkovic et al., 2002). SAHA 
failed to alter body weight or water intake in the DOCA-salt rats; further, UNX rats 
treated with SAHA also failed to gain weight compared to vehicle-treated rats. There 
was no change in the food intake among the groups. Systolic blood pressure was 
increased in DOCA-salt rats when compared with UNX rats and this increase was 
attenuated by SAHA treatment (Table 1). The DOCA-salt rats showed left and right 
ventricular hypertrophy (increased LV+septum and RV wet weights) at 4 weeks, 
compared with UNX rats (Table 1) and this increase in organ weights of both 
ventricles was attenuated by SAHA treatment. DOCA-salt rats showed increased wet 
weights of liver, spleen and kidney that were unaltered by SAHA treatment (Table 1). 
Plasma malondialdehyde concentrations, as a measure of oxidative stress, were 
increased in DOCA-salt rats; this increase was attenuated by SAHA treatment (Table 
1). 
 
Rat chemokines and cytokines; matrix metalloproteinase activity 
 A chemokine/cytokine array kit was used to compare the effect of SAHA on plasma 
inflammatory mediators from DOCA-salt rats rather than ELISAs for individual 
cytokines since cytokines show marked redundancy. Visual inspection of Figure 1 
reveals that SAHA suppressed the expression of all of these markers, except for 
CINC1 which was overexpressed, while it was difficult to deduce any change for 
RANTES, TIMP1 and LIX. Quantitative analysis by densitometry of the blots (Figure 
2) could only reliably place statistical significance on the more highly expressed 
proteins (IL1, IP10, IL1ra, GMCSF, IL10, fractalkine, VEGF, MIG). We conclude 
that SAHA has broad-spectrum anti-inflammatory activity in these DOCA-salt treated 
rats, clearly impacting the “cytokine storm” by reducing plasma concentrations of a 
diverse range of pro-inflammatory proteins. 
 
Further, SAHA, a hydroxamate derivative and other hydroxamates (Leung et al, 2000; 
Halili et al, 2009) could possibly inhibit matrix metalloproteinase (MMP) expression 
or activity. To address this issue, we measured the expression of human MMPs and 
tissue inhibitors of matrix metalloproteinase (TIMPs) in culture medium of human 
monocyte-derived macrophages. Addition of SAHA (5 or 50 M) did not change 
MMP expression (data not shown). Further, using gelatin zymography, SAHA at 5 or 
50 M showed no inhibition of MMP-2 and -9 activity whereas at 500 M, it showed 
a modest inhibition of MMP-2 activity (data not shown). 
 
Left ventricular structure and function 
 
Hearts from DOCA-salt rats showed increased diastolic stiffness that was attenuated 
by SAHA treatment (Table 1). The collagen content in the left ventricle of UNX rats 
(perivascular 20.03.6%, n=4, Figure 2; interstitial 1.10.1%, n=5; Figure 3) was 
increased in DOCA-salt rats (perivascular, 56.62.5%, n=4; interstitial 9.20.9%, 
n=5; Figure 3). These increases were attenuated by treatment with SAHA in the 
DOCA-salt rats (DOCA+SAHA: perivascular 381.2%, n=4; interstitial 4.60.5%, 
n=5). Collagen deposition was unaltered by SAHA treatment in the normotensive 
UNX rats (UNX+SAHA: perivascular 19.00.8%, n=4; interstitial 1.20.1%, n=5; 
Figure 3).   
 
Spatial location of monocyte/macrophages (Figure 4) shows monocyte/macrophages 
in the left ventricle of UNX rats in very low numbers and always as single cells. The 
density of monocyte/macrophages found in the left ventricle of DOCA-salt rats was 
significantly greater than in UNX, and these cells were usually found in clusters of 
cells located at scar sites and throughout the interstitium and the areas of fibrosis. 
Very few infiltrating cells were found in scar tissue in DOCA-salt rats treated with 
SAHA, predominantly due to the decreased area of scar tissue within the left 
ventricle; few infiltrating cells were found in the perivascular areas (Figure 4).  
 
Microelectrode studies  
 
Single cell microelectrode studies were performed on isolated left ventricular 
papillary muscles to quantify the changes in electrical conductance in the 
hypertrophied hearts. In hearts from the DOCA-salt rats, APD was markedly 
increased at 20%, 50% and 90% of repolarisation when compared with UNX hearts. 
Treatment with SAHA decreased the resting membrane potential and action potential 
amplitude in both treatment groups (Table 1). The increased action potential duration 
at 20% and 90% of repolarization in the DOCA-salt rat was reduced by SAHA 
treatment (Table 1).  
 
Organ bath studies 
 
Thoracic aortic rings from DOCA-salt rats showed unaltered maximal responses to 
noradrenaline and sodium nitroprusside across all treatment groups (Figure 5A & 5B) 
with minimal relaxation responses to acetylcholine suggesting pronounced endothelial 
dysfunction (Figure 5C). Treatment with SAHA normalized this decreased response 
to acetylcholine.  
 
 
DISCUSSION 
 
Cardiovascular remodelling following chronic pathophysiological stress includes 
hypertension, hypertrophy and fibrosis, ultimately leading to an enlarged and more 
rigid myocardium, together with electrical conduction changes and endothelial 
dysfunction (Weber, 1996; Weber et al, 1993). While histone deacetylase inhibitors 
(HDACi) have been reported to be anti-inflammatory (Halili et al, 2009) and to 
attenuate cardiac hypertrophy (Antos et al, 2003; Gallo et al, 2008; Kee et al, 2006; 
Kong et al, 2006), we have now shown that the broad spectrum (class I and II) 
HDACi, SAHA (25 mg kg
-1
 day
-1
), can also attenuate perivascular and interstitial 
cardiac fibrosis, as well as hypertension, electrical changes and endothelial 
dysfunction associated with DOCA-salt induced hypertension in rats. Functionally, 
this decreased fibrosis was associated with markedly reduced cardiac stiffness. 
 
Inflammation is the key initiator of cardiac extracellular matrix remodelling by 
allowing the infiltration of inflammatory cells and activating fibroblasts (Nicoletti & 
Michel, 1999; Rutschow et al, 2006). A single oral dose (0.1-25 mg kg
-1
) of SAHA 
reduced cytokines (TNF, IL1, IL6, IFN) in the circulation of mice treated with 
LPS (Leoni et al, 2002). This is in accordance with our findings of diverse cytokine 
suppression monitored in DOCA-salt rats after chronic SAHA treatment, and is 
consistent with a broad-spectrum anti-inflammatory response to SAHA in rats.  
 
Responses to injury in the heart share many features in common with wound healing, 
inflammation and fibrosis observed in other tissues, including lung, liver, kidney and 
skin (Brown et al, 2005b; Friedman, 1999; Kupper & Groves, 1995; Sime et al, 1998; 
Weber, 1997; Zalewski & Shi, 1997). The common sequence of events that occurs in 
response to an inflammatory insult can be summarized as haemostasis; recruitment of 
circulating immune-inflammatory cells; macrophage activation; activation of 
fibroblasts and formation of a provisional matrix; and remodelling of the 
granulomatous scar (Brown et al, 2005b; Davidson, 1992; Weber, 1996). These 
responses from activated immune-inflammatory cells are regulated by specific 
circulating cytokines and growth factors (Brown et al, 2005b). In relation to 
inflammation and cardiac fibrosis, our previous study showed that a phospholipase A2 
inhibitor, KH-064, also markedly attenuated fibrosis in the hypertensive heart without 
decreasing the infiltration of inflammatory cells (Levick et al, 2006). Other common 
anti-inflammatory drugs such as aspirin also decrease collagen deposition and prevent 
oxidative stress-induced cardiovascular remodelling in infarcted rats and angiotensin 
II-induced hypertensive rats, respectively (Van Kerckhoven et al, 2000; Wu et al, 
2004).  
 
The importance of histone acetylation in the aetiology of cardiac remodelling has 
been highlighted by the regulation of the hypertrophic response of the heart by 
selective HDACi (Gusterson et al, 2003; Kong et al, 2006; Lu et al, 2000; Zhang et 
al, 2002). HDACs modulate the divergent stress-response pathways activated during 
cardiac remodelling (Kong et al, 2006; McKinsey & Olson, 2004). The precise 
HDAC isoforms responsible for cardiovascular remodelling in vivo are still 
controversial, with evidence that class I (HDACs 1, 2, 3, 8 and 11), II (HDACs 4, 5, 
6, 7, 9 and 10) and III (sirtuins) HDACs have pro-hypertrophic, anti-hypertrophic and 
anti-apoptotic functions in cardiomyocytes, respectively (McKinsey & Kass, 2007; 
McKinsey & Olson, 2004; Verdin et al, 2003; Zhang et al, 2002). 
 
HDACs and pro-inflammatory cytokines have been implicated in a wide variety of 
inflammatory diseases (Halili et al, 2009), including rheumatoid arthritis (Choo et al, 
2008), systemic lupus erythematosus (SLE) (Blanchard & Chipoy, 2005), asthma 
(Bhavsar et al, 2008), inflammatory lung diseases (Adcock et al, 2005; Bhavsar et al, 
2008), atherosclerosis, hemorrhagic shock, diabetes, inflammatory bowel diseases, 
osteoporosis, macular degeneration, neurodegenerative and CNS diseases (Halili et al, 
2009), with therapeutic effects of HDACi in many animal models of inflammatory 
diseases (Blanchard & Chipoy, 2005). SAHA suppressed cytokine production and 
nitric oxide release both in vivo and in vitro, possibly by regulating the expression of 
genes that control the synthesis of cytokines and nitric oxide or hyperacetylating other 
targets (Leoni et al, 2002). There have been relatively few studies where rats have 
been chronically dosed with SAHA. Wise et al (2008) administered SAHA at oral 
doses of 0 to 150 mg kg
-1
 as a suspension in water with 1.0% (w/v) 
carboxymethylcellulose sodium and 0.5% (v/v) polysorbate 80 for up to 14 weeks to 
test changes in male and female fertility in rats. In the in vivo model of concanavalin 
A-induced hepatic injury, a model that is TNF and IL-18 dependent (Faggioni et al, 
2000), a single dose of SAHA (50 mg kg
-1
) reduced the injury by 50% (Leoni et al, 
2002). Oral treatment in mice with SAHA (50 mg kg
-1
) for 8 days reduced the clinical 
and cytokine abnormalities in dextran sulphate sodium-induced colitis (Glauben et al, 
2006). SAHA was also effective at doses of less than 50 mg kg
-1
 as an anti-
inflammatory compound in rodent models of rheumatic arthritis, endotoxemia, 
hepatic injury and colitis (Leoni et al, 2002; Lin et al, 2007). In combination, this in 
vivo and in vitro information strongly suggests that the dose of SAHA used in this 
study, 25mg kg
-1
 day
-1
, is in the range used in previous studies and is an effective dose 
to show anti-inflammatory effects (Halili et al, 2009). 
 
Inappropriate fibroblast hyperplasia is a hallmark of fibrosis. Myofibroblasts, which 
are specially differentiated fibroblasts exhibiting contractile properties and expressing 
smooth muscle -actin, play an important role in contracture of the granulomatous 
wound (Brown et al, 2005b). Myofibroblasts have been identified in myocardial scars 
as the predominant source of collagen (Willems et al, 1994). Macrophages are also 
localized with myofibroblasts in the NO-deficient model of fibrosis (Koyanagi et al, 
2000) and isoprenaline-induced model of myocardial injury (Nakatsuji et al, 1997). In 
addition, macrophage infiltration preceded the presence of myofibroblasts and clusters 
of macrophages were located in close proximity to myofibroblasts (Vyalov et al, 
1993), suggesting a role for inflammation in fibroblast activation and differentiation. 
Further, MMPs are important enzymes in regulating cardiovascular remodelling. 
Some hydroxamate derivatives inhibit the expression or activity of MMPs (Leung et 
al, 2000; Halili et al 2009), but for SAHA we did not observe regulatory effects on 
the secretion of MMP-1, -2, -3, -8, -9, -10 or -13 or TIMP-1, -2 or -4 into the culture 
medium of human monocyte-derived macrophages as measured by antibody array. In 
gelatin zymography experiments, SAHA (5 or 50 M) had no effect on purified 
MMP-2 or -9 activities whereas the high concentration of 500 M showed a modest 
inhibition of MMP-2 activity (data not shown). Further, responses to MMP inhibitors 
differ from those shown with SAHA in this study: the tetracycline, doxycycline, did 
not change collagen area fraction during post-infarction left ventricular remodelling 
(Villarreal et al, 2003). This suggests that an anti-inflammatory mechanism for 
SAHA, reducing circulating cytokines, and thereby reducing infiltrating inflammatory 
cells and arachidonic acid metabolites, rather than MMP inhibition, may be 
responsible for the reduced collagen deposition in the perivascular and interstitial 
areas in the DOCA-salt hypertensive heart. 
 
Our results also show that treatment with SAHA attenuated the increased wet weights 
of DOCA-salt hypertensive hearts. Since inflammation initiates fibrosis without 
affecting hypertrophy (Kagitani et al, 2004; Kuwahara et al, 2004), the anti-
inflammatory effects of SAHA may have little to do with this attenuation of 
ventricular hypertrophy. Class I HDACs (HDAC 1, 2 and 3) exhibited pro-
hypertrophic properties (McKinsey & Kass, 2007; McKinsey & Olson, 2004; Trivedi 
et al, 2007; Verdin et al, 2003) and also increased cardiac myocyte proliferation 
during cardiac development in transgenic mice studies (Trivedi et al, 2008). Further, 
the HDACi, valproic acid, reduced ventricular hypertrophy and remodelling in 
infarcted rats probably by repressing pro-hypertrophic genes (Lee et al, 2007). This 
suggests that compounds that inhibit at least class I HDACs attenuate ventricular 
hypertrophy probably by repressing pro-hypertrophy genes or inducing cell cycle 
arrest.  
 
Cardiac remodelling induced by DOCA-salt treatment is characterized by a decrease 
in the expression, current density and function of cardiac potassium channels (Ito and 
Ik), prolonging the action potential (Momtaz et al, 1996; Capuano et al, 2002). The 
DOCA-salt rat suffers from cardiac electrical disturbances characterized by an 
increase in spontaneous arrhythmias (Momtaz et al, 1996; Capuano et al, 2002). This 
prolongation of the action potential can be markedly attenuated by treatment with the 
NO-precursor, L-arginine (Fenning et al, 2005) or a selective antagonist of ETA 
receptors (Allan et al, 2005) concurrent with decreased cardiac fibrosis. Further, 
circulation pro-inflammatory compounds such as TNF can prolong the action 
potential by suppressing the delayed rectifier K
+
 current (Wang et al, 2004). Thus, the 
improved electrical conductance of the DOCA-salt hearts with SAHA treatment can 
be attributed to its anti-fibrotic effects. 
 
The increase in systolic blood pressure in the DOCA-salt rats was attenuated with 
SAHA treatment. Recent studies point to class III HDAC enzymes (sirtuins) as key 
regulators of vascular endothelial homeostasis controlling angiogenesis, vascular tone 
and endothelial dysfunction (Potente & Dimmeler, 2008). Although SAHA has been 
identified as a broad spectrum class I and class II HDACi, it was shown to 
differentially regulate the sirtuins. In cultured neural cells, SAHA and other class I 
and II HDACi upregulated SIRT2, SIRT4 and SIRT7 and downregulated SIRT1, 
SIRT5 and SIRT6 gene expression (Kyrylenko et al, 2003). This supports the 
possibility that improved endothelial function and blood pressure in our study may be 
due to SAHA modulating the expression of sirtuins, which are vital in vascular 
endothelial homeostasis.  
 
In summary, our results have shown that at least one HDACi has the potential to 
suppress cardiac fibrosis during development of hypertension in the rat heart. 
Although we attribute the observed pharmacological effects to broad-spectrum anti-
inflammatory activity, the possibility that the inhibition of global lysine acetylation, 
which alters various protein complexes and regulators of many major cellular 
functions including myocardial and vascular cell functions (Choudhary et al, 2009), in 
being partly responsible cannot be ruled out. The results suggest that modulation of 
cardiac histone or non-histone protein acetylation by small molecule HDACi may be a 
viable approach to targeting intracellular signalling pathways that lead to cardiac 
remodelling and fibrosis. Since the HDACi studied is already available in humans for 
the treatment of lymphomas, the compound could be further examined in a clinical 
setting for preventing cardiac remodelling, particularly cardiac fibrosis.  
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Legends 
 
Table I: Physiological parameters of uninephrectomied (UNX), uninephrectomied 
and deoxycorticosterone-treated (DOCA), UNX+suberoylanilide hydroxamic acid 
(SAHA) and DOCA+SAHA-treated rats. Values are mean ± SEM; number of 
experiments in parentheses. LV, left ventricle; RV, right ventricle; #P<0.05 vs. UNX; 
*P<0.05 vs. DOCA. LV mass calculated according to Litwin et al (1994). 
 
Figure 1:  Suppression of inflammatory cytokines by SAHA treatment in vivo. Serum 
cytokines from (A) DOCA-treated rats (B) DOCA+SAHA-treated rats. Each blot 
represents three independent experiments and is numbered 1, IL1a; 2, CINC2a/b; 3, 
IL17; 4, IP10; 5, IL2; 6, TNFa; 7, IL4; 8, MIP1a; 9, IFNg; 10, IL13; 11, IL1b; 12, 
CINC3; 13, IL1ra; 14, CNTF; 15, IL3; 16, GMCSF; 17, IL6; 18, CINC1; 19, 
RANTES; 20, thymus chemokine; 21, TIMP1; 22, LIX; 23, fractalkine; 24, L-
selectin; 25, VEGF; 26, MIG; 27, sICAM; 28, IL10; 29, MIP3; 30 (control). 
 
Figure 2: Densitometric measurement of relative concentrations in rat plasma of 
cytokines/chemokines based on % optical density of positive control. Plasma from 
DOCA ( ) and DOCA+SAHA ( ) treated rats. All values are mean  SEM of 
three independent experiments (P < 0.05 = *, P < 0.01 = **, P < 0.001 = ***). 
 
Figure 3: Picrosirius red staining of left ventricular perivascular collagen deposition 
(A-D) and of left ventricular interstitial collagen deposition (E-H) (magnification, 
x40) in UNX (A,E), DOCA (B,F), UNX+SAHA (C,G), DOCA+SAHA (D,H)-treated 
rats and graphical representation of left ventricular perivascular collagen (I) and 
interstitial collagen (J) deposition (#, p<0.05 vs UNX; *, p<0.05 vs DOCA); collagen 
is stained light red. 
 
Figure 4: Haematoxylin and eosin staining of infiltrating inflammatory cells of left 
ventricular interstitial region (magnification, x40) in UNX (A), DOCA (B), 
UNX+SAHA (C), DOCA+SAHA (D)-treated rats. 
 
Figure 5: Cumulative concentration-response curves for noradrenaline (A), sodium 
nitroprusside (B) and acetylcholine (C) in thoracic aortic rings from UNX, DOCA, 
UNX+SAHA and DOCA+SAHA-treated rats (#P< 0.05 vs. UNX; *P< 0.05 vs. 
DOCA). 
 
 
 
 
 
 
 
 
Table I 
 
Parameter 
UNX 
(4 weeks) 
UNX+ 
SAHA 
(4 weeks) 
DOCA 
(4 weeks) 
DOCA+ 
SAHA 
(4 weeks) 
Initial body weights (g) 3585 
(n=6) 
34615 
(n=6) 
3536 
(n=6) 
3398 
(n=6) 
Final body weights (g)  4416 
(n=6) 
35312# 
(n=6) 
3518# 
(n=6) 
35112# 
(n=6) 
Daily food intake (g) 313.2 
(n=6) 
21.34 
(n=6) 
26.64 
(n=6) 
24.24 
(n=6) 
Daily water intake (g) 62.710 
(n=6) 
56.47 
(n=6) 
155.933.2# 
(n=6) 
19235# 
(n=6) 
Systolic blood pressure (mmHg) 
0 weeks 
1071.3 
(n=6) 
1083.1 
(n=6) 
1083.1 
(n=6) 
1131.6 
(n=6) 
Systolic blood pressure (mmHg) 
2 weeks 
1280.7 
(n=6) 
1266.9 
(n=6) 
1767.3# 
(n=6) 
1434.5* 
(n=6) 
Systolic blood pressure (mmHg) 
4 weeks 
1351.7 
(n=6) 
1293.0 
(n=6) 
1863.6# 
(n=6) 
1601.6* 
(n=6) 
Diastolic stiffness constant () 20.30.8 
(n=6) 
17.00.6 
(n=6) 
32.31.7# 
(n=6) 
24.80.9* 
(n=6) 
LV+septum 
 (mg g
-1
 body wt) 
1.70.07 
(n=6) 
2.10.04 
(n=6) 
3.10.1# 
(n=6) 
2.40.07* 
(n=6) 
RV  
(mg g
-1
 body wt) 
0.300.03 
(n=6) 
0.380.01 
(n=6) 
0.510.04# 
(n=6) 
0.420.03* 
(n=6) 
Liver  
(mg g
-1
 body wt) 
34.80.9 
(n=6) 
35.11.5 
(n=6) 
52.41.9# 
(n=6) 
48.92.1 
(n=6) 
Spleen  
(mg g
-1
 body wt) 
2.90.2 
(n=6) 
3.40.3 
(n=6) 
4.40.1# 
(n=6) 
3.80.5 
(n=6) 
Kidneys  
(mg g
-1
 body wt) 
4.30.1 
(n=6) 
4.20.2 
(n=6) 
8.50.2# 
(n=6) 
8.40.6 
(n=6) 
Resting membrane potential 
(mV) 
-71.13.7 
(n=8) 
-63.00.9# 
(n=4) 
-74.31.7 
(n=9) 
-61.33.5* 
(n=10) 
Action potential amplitude 
(mV) 
83.85.3 
(n=8) 
56.73.2# 
(n=4) 
81.14.5 
(n=9) 
55.13.7* 
(n=10) 
Action potential duration  
at 20% (msec) 
6.81.1 
(n=8) 
11.81.6# 
(n=4) 
24.54.1# 
(n=9) 
16.71.2* 
(n=10) 
Action potential duration  
at 50% (msec) 
16.42.0 
(n=8) 
22.35.8 
(n=4) 
40.55.9# 
(n=9) 
31.32.9# 
(n=10) 
Action potential duration  
at 90% (msec) 
34.43.5 
(n=8) 
44.28.5 
(n=4) 
84.28.1# 
(n=9) 
62.35.1* 
(n=10) 
Force of contraction (mN) 1.10.4 
(n=8) 
0.80.1 
(n=4) 
0.340.01 
(n=9) 
3.81.0* 
(n=10) 
Plasma malondialdehyde 
(MDA) concentration (mol L-1) 
19.70.7  
(n=5) 
27.30.8* 
(n=5) 
21.00.8  
(n=5) 
24.70.3** 
(n=5) 
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